D. E. Shaw & Co., Inc. Inhibrx, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $938,786 - $1.54 Million	-55,353 Reduced 60.93%	35,497 $921,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $191,695 - $281,984	-10,390 Reduced 10.26%	90,850 $1.71 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $636,093 - $1.05 Million	31,521 Added 45.21%	101,240 $2.49 Million
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $593,972 - $1.27 Million	-51,293 Reduced 42.39%	69,719 $1.25 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $724,336 - $2.15 Million	85,016 Added 236.18%	121,012 $1.37 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $441,299 - $958,034	22,187 Added 160.67%	35,996 $802,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $369,390 - $635,490	13,809 New	13,809 $603,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.